Publikationen (66) Publikationen von JOSE ANTONIO COSTOYA PUENTE

2024

  1. AB067. New drug development for the use of PARP1-E2F1 transcriptional inhibitors in the treatment of glioblastoma

    Chinese clinical oncology, Vol. 13, pp. AB067

  2. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2023

  1. A New Opportunity for “Old” Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

  2. Cancer cells escape the immune system by increasing stemness through epigenetic reprogramming

    Cellular and Molecular Immunology

  3. Inhibiting HER3 Hyperphosphorylation in HER2-Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells

    Small, Vol. 19, Núm. 50

2022

  1. Development of a biosensor based on a new marine luciferase fused to an affibody to assess Her2 expression in living cells

    Analytica Chimica Acta, Vol. 1221

  2. Development of a nanocapsule-loaded hydrogel for drug delivery for intraperitoneal administration

    International Journal of Pharmaceutics, Vol. 622

  3. Editorial: Cellular stress in blood cancer: Pathophysiology and therapeutic opportunities

    Frontiers in Oncology

  4. New insights into the relevance of mobile DNA to cancer resistance in blind mole rats: new lessons for cancer therapy

    Cellular and Molecular Immunology

2021

  1. From neural stem cells to glioblastoma: A natural history of GBM recapitulated in vitro

    Journal of Cellular Physiology, Vol. 236, Núm. 11, pp. 7390-7404

  2. SARS-CoV-2 infection in K18-ACE2 transgenic mice replicates human pulmonary disease in COVID-19

    Cellular and Molecular Immunology

2020

  1. Immortalization of a cell line with neural stem cell characteristics derived from mouse embryo brain

    Developmental Dynamics, Vol. 249, Núm. 1, pp. 112-124

  2. Integración neuroendocrina

    Fisiología humana (McGraw Hill Education México)

  3. Parp1 deficiency reduces tumour growth by decreasing e2f1 hyperactivation: A novel mechanism in the treatment of cancer

    Cancers, Vol. 12, Núm. 10, pp. 1-11

2019

  1. A Bio-inspired Hypoxia Sensor using HIF1a-Oxygen-Dependent Degradation Domain

    Scientific Reports, Vol. 9, Núm. 1

  2. Expression of myostatin in human hematopoietic cells unveils novel autocrine/paracrine actions for the hormone

    Journal of Cellular Physiology, Vol. 234, Núm. 5, pp. 7236-7246

2018

  1. NK cell-based glioblastoma immunotherapy

    Cancers, Vol. 10, Núm. 12

2017

  1. Uncoupling Oncogene-Induced Senescence (OIS) and DNA Damage Response (DDR) triggered by DNA hyper-replication: Lessons from primary mouse embryo astrocytes (MEA)

    Scientific Reports, Vol. 7, Núm. 1

2015

  1. RB mutation and RAS overexpression induce resistance to NK cell-mediated cytotoxicity in glioma cells

    Cancer Cell International, Vol. 15, Núm. 1